Fenwick represented Eyconis, Inc. in connection with their formation and $150 million capital raise. Eyconis was formed and launched by Ascendis Pharma A/S, Frazier Life Sciences, and an investor syndicate that included Frazier, RA Capital Management, venBio, and HealthQuest Capital.
Eyconis has exclusive rights granted by Ascendis Pharma to develop and commercialize TransCon ophthalmology products globally. More information can be obtained from the company’s announcement.
The transaction was led by corporate partner Matt Rossiter and included associates Joanna Xu and Tempestt Edward; and technology transactions partner Jake Handy.